Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants

Transplantation

Volumn 92, Issue 5, 2011, Pages 570-574

  Jimenez Zepeda, Victor H ^a   Heilman, Raymond L ^a   Engel, Rodney A ^a   Carey, Elizabeth J ^a   Freeman, Ciara ^a   Rakela, Jorge ^a   Mulligan, David C ^a   Fonseca, Rafael ^a   Stewart, Alexander Keith ^a  

^a MAYO CLINIC   (United States)

Author keywords

Monoclonal gammopathy of undetermined significance; Multiple myeloma; Posttransplant lymphoproliferative disorders; Serum protein electrophoresis; Transplantation

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DEATH; DISEASE COURSE; FEMALE; GAMMOPATHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MONOCLONAL IMMUNOGLOBULINEMIA; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PANCREAS TRANSPLANTATION; POLYCLONAL IMMUNOGLOBULINEMIA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; BLOOD PROTEIN ELECTROPHORESIS; CHILD; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; RISK FACTORS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052422338     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318225db2c     Document Type: Article

References (25)

1. Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance. Rev Clin Exp Hematol 2002; 6: 225.
2. Durie BG, Kyle RA, Belch A, et al. Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4: 379.
3. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 134: 573.
4. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: Diagnosis and treatment. Mayo Clin Proc 2006; 81: 693.
5. Rajkumar SV, Lacy MQ, Kyle RA. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Rev 2007; 21: 255.
6. Madan S, Greipp PR. The incidental monoclonal protein: Current approach to management of monoclonal gammopathy of undetermined significance (MGUS). Blood Rev 2009; 23: 257.
7. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: The original Mayo Clinic series 25 years later. Mayo Clin Proc 2004; 79: 859.
8. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study. Blood 2009; 113: 5412.
9. Rostaing L, Modesto A, Abbal M, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance in transplant patients. Am J Nephrol 1994; 14: 187.
10. Hardiman KL, Horn S, Manoharan A, et al. Rheumatic autoantibodies in the sera of patients with paraproteins. Clin Exp Rheumatol 1994; 12: 363.
11. Daoud MS, Lust JA, Kyle RA, et al. Monoclonal gammopathies and associated skin disorders. J Am Acad Dermatol 1999; 40: 507.
12. Idilman R, Colantoni A, De Maria N, et al. Lymphoproliferative disorders in chronic hepatitis C. J Viral Hepat 2004; 11: 302.
13. Amara S, Dezube BJ, Cooley TP, et al. HIV-associated monoclonal gammopathy: A retrospective analysis of 25 patients. Clin Infect Dis 2006; 43: 1198.
14. Radl J, Valentijn RM, Haaijman JJ, et al. Monoclonal gammapathies in patients undergoing immunosuppressive treatment after renal transplantation. Clin Immunol Immunopathol 1985; 37: 98.
15. Zent CS, Wilson CS, Tricot G, et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood 1998; 91: 3518.
16. Renoult E, Bertrand F, Kessler M. Monoclonal gammopathies in HBsAg-positive patients with renal transplants.NEngl J Med 1988; 318: 1205.
17. Caforio AL, Gambino A, Fortina AB, et al. Monoclonal gammopathy in heart transplantation: Clinical significance and risk factors. J Heart Lung Transplant 2001; 20: 237.
18. Passweg J, Thiel G, Bock HA. Monoclonal gammopathy after intense induction immunosuppression in renal transplant patients. Nephrol Dial Transplant 1996; 11: 2461.
19. Lemoine A, Pham P, Azoulay D, et al. Detection of gammopathy by serum protein electrophoresis for predicting and managing therapy of lymphoproliferative disorder in 911 recipients of liver transplants. Blood 2001; 98: 1332.
20. Badley AD, Portela DF, Patel R, et al. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transpl Surg 1996; 2: 375.
21. Pageaux GP, Bonnardet A, Picot MC, et al. Prevalence of monoclonal immunoglobulins after liver transplantation: Relationship with posttransplant lymphoproliferative disorders. Transplantation 1998; 65: 397.
22. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409.
23. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431.
24. Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for liver allograft rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection. Hepatology 2000; 31: 792.
25. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749.